Disülfiram etkileşimleri

WARNING Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. (Disülfiram etiketi, Kutulu uyarı)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (Disülfiram etiketi, Kontrendikasyonlar)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (Bosentan etiketi, İlaç etkileşimleri)

…reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (Dronabinol etiketi, Kontrendikasyonlar)

Avoid using NUMBRINO in patients taking disulfiram. (Kokain etiketi, İlaç etkileşimleri)

Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (Masitentan etiketi, İlaç etkileşimleri)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (Disülfiram etiketi, Kontrendikasyonlar)

Alcohols, Disulfiram: Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. (Tinidazol etiketi, İlaç etkileşimleri)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (Aminofilin etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (Diklofenak etiketi, İlaç etkileşimleri)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS RECEIVING PHENYTOIN AND ITS CONGENERS, SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION. (Disülfiram etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

…(cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels… (Fosfenitoin etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (Lakozamid etiketi, İlaç etkileşimleri)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (Meloksikam etiketi, İlaç etkileşimleri)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (Nateglinid etiketi, İlaç etkileşimleri)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (Ramelteon etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (Rosuvastatin etiketi, İlaç etkileşimleri)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (Selekoksib etiketi, İlaç etkileşimleri)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (Teofilin etiketi, İlaç etkileşimleri)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (Torasemid etiketi, İlaç etkileşimleri)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (Disülfiram etiketi, İlaç etkileşimleri)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (Zafirlukast etiketi, Önlemler)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (Amitriptilin etiketi, İlaç etkileşimleri)

Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status, the disulfiram should be discontinued if such signs appear. (Disülfiram etiketi, İlaç etkileşimleri)

Alcohol: Exceptional cases have been reported of a disulfiram-like reaction to alcohol, characterized by flushing, rash, peripheral edema, nausea and headache. (Ketokonazol etiketi, İlaç etkileşimleri)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (Lopinavir ve ritonavir etiketi, İlaç etkileşimleri)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (Omeprazol etiketi, İlaç etkileşimleri)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (Omeprazol ve sodyum bikarbonat etiketi, İlaç etkileşimleri)

Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered cefotaxime and ethanol. (Sefotaksim etiketi, İlaç etkileşimleri)

Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (Terbinafin etiketi, İlaç etkileşimleri)

Toremifene is a weak inhibitor of CYP2C9. (Toremifen etiketi, İlaç etkileşimleri)

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9. (Vardenafil etiketi, İlaç etkileşimleri)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (Venlafaksin etiketi, İlaç etkileşimleri)

The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Akamprosat etiketi, İlaç etkileşimleri)